| Document |
Document Title |
|
WO/2015/031295A1 |
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...
|
|
WO/2015/030189A1 |
Provided is a compound which exhibits bone formation acceleration activity (and/or bone resorption suppression activity). The compound is either a compound having a general formula (I) (wherein the substituents are as defined in the desc...
|
|
WO/2015/025859A1 |
A radiation-sensitive resin composition that comprises a polymer having an acid-dissociable group-containing structural unit, a compound comprising a radiolytic onium cation and a counter anion, and a solvent, wherein the counter anion h...
|
|
WO/2015/008779A1 |
The present invention relates to a compound represented by formula (I) (In the formula, Ar is a substituted or unsubstituted aromatic group, R is a substituted or unsubstituted hydrocarbon group, or a substituted or unsubstituted heteroc...
|
|
WO/2015/002230A1 |
The present invention relates to compounds (I), which have RORγt inhibitory effects, and salts thereof. In formula (I), each notation is as described in the Specification. (I)
|
|
WO/2014/206349A1 |
The present invention relates to an oxa-thia-bicyclo[3.2.1]octane derivative, a preparation method, and use of same, and particularly to an oxa-thia-bicyclo[3.2.1]octane derivative represented by the general formula (I) or a hydrate, a s...
|
|
WO/2014/202168A1 |
Compounds of the formula I in which R1, R4, R6, R, X1, X2, X3, X4, q and W have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, card...
|
|
WO/2014/197169A1 |
A method for protecting a phenol group on a precursor compound is provided. The method includes reacting the phenol group with dihydropyran in an acid catalyzed protection reaction and quenching the protection reaction with a strong base...
|
|
WO/2014/195553A1 |
The invention relates to a compound of formula (I), where R is selected from a methyl group or an ethyl group (I), the hydroxy acid forms of said compound, the pharmaceutically acceptable salts of said hydroxy acids, and pharmaceutically...
|
|
WO/2014/191535A1 |
The present invention relates to a compound of formula (I): wherein: X is methyl or chlorine; R1 is fluorine or bromine; R2 is ethynyl, C1-C3alkoxy, C1-C3haloalkoxy, or C1-C3alkoxy-C1-C3alkoxy-; and Q is a pyran-3,5-dione-4-yl, a thiopyr...
|
|
WO/2014/191578A1 |
Drug conjugates of formula [D-(X)b-(AA)w-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein: A is selected from (II) and...
|
|
WO/2014/192023A1 |
The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use ...
|
|
WO/2014/191534A1 |
The present invention relates to a compound of formula (I): wherein: X is methyl or chlorine; R1 is fluorine or bromine; R2 is ethynyl, C1-C3alkoxy, C1-C3haloalkoxy, or C1-C3alkoxy-C1-C3alkoxy-; and Q is a pyran-3,5-dione-4-yl, a thiopyr...
|
|
WO/2014/189926A1 |
A method to prepare coumalic acid comprising (a) heating a solution in dichloroethane of malic acid and sulfuric acid or a solution in dichloroethane of malic acid and a perfluorosulfonic acid or (b) adding an acid comprising sulfuric ac...
|
|
WO/2014/189347A1 |
The present invention provides a novel compound isolated from a plant of the genus Quamoclit and a method for preparing a novel compound isolated from a plant of the genus Quamoclit through chemical synthesis, and relates to a novel comp...
|
|
WO/2014/184311A1 |
The present invention relates to a method for producing dehydro rose oxide by reacting isoprenol and prenal in the presence of at least one sulfonic acid of formula R1-SO3H as catalyst, wherein R1 is selected from phenyl which carries 2 ...
|
|
WO/2014/177486A1 |
The invention relates to a method for producing 2-substituted 4-hydroxy-4-methyl-tetrahydropyrans.
|
|
WO/2014/177593A1 |
The present invention relates to Amorfrutin analogues and stereoisomeric forms, solvates, hydrates, conjugates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of ...
|
|
WO/2014/178381A1 |
Provided is a new compound having glycogen synthase activation potency, but minimal activation of receptor PPAR, and a high degree of safety. A compound represented by general formula [I], or a pharmaceutically acceptable salt thereof....
|
|
WO/2014/177484A1 |
The invention relates to a method for producing 2-substituted 4-hydroxy-4-methyl-tetrahydropyrans.
|
|
WO/2014/174126A1 |
The invention relates to derivatives of pyrylium of formula I where the substituents have the meaning defined in the description, used as fluorescent nitric oxide sensors.
|
|
WO/2014/168211A1 |
Disclosed is a method for producing 2-(4-tetrahydropyranyl)imidazole and/or an acid salt thereof, which comprises a step of producing 2-(4-tetrahydropyranyl)imidazole represented by general formula (4) and/or an acid salt thereof from a ...
|
|
WO/2014/156184A1 |
[Problem] To provide: an organic photoelectric conversion element which has good response speed, carrier transport properties (sensitivity) and heat resistance; and an imaging element which is provided with this organic photoelectric con...
|
|
WO/2014/160649A1 |
This invention pertains generally to antibacterial organic compounds of Formula I as described herein, and pharmaceutical compositions containing such compounds. In certain aspects, the invention pertains to treating infections caused by...
|
|
WO/2014/146606A1 |
The present invention relates to a C-triaryl glucoside SGLT-2 inhibitor shown as formula (I), preparation methods therefor, pharmaceutical compositions thereof and uses thereof for treating diseases that benefit from inhibiting SGLT-2. S...
|
|
WO/2014/146491A1 |
The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
|
|
WO/2014/139447A1 |
Provided in the present invention is a crystal form A of (1S)-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1,6-dideoxy-D-glu
cose, characterized in that X-ray powder diffraction as shown by angle 2θ has diffraction peaks around 3.56, 5.42, 10....
|
|
WO/2014/141979A1 |
The present invention is a radiation-sensitive resin composition which contains a radiation-sensitive acid generator and a polymer having a structural unit that contains an acid-cleavable group, and wherein the radiation-sensitive acid g...
|
|
WO/2014/142329A1 |
An organic charge transfer complex obtained from an electron acceptor molecule and an electron donor molecule, wherein the electron acceptor molecule is PDC or a PDC derivative.
|
|
WO/2014/138053A1 |
In one aspect, the invention relates to compounds having the formula: (I) where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In anoth...
|
|
WO/2014/130613A2 |
Compounds of Formula (I) are useful as modulators of glycosylation. Compounds of Formula (I) have the following structure: (I) and the definitions of the other variables are provided herein.
|
|
WO/2014/129268A1 |
Provided are: a liquid crystal compound satisfying at least one property such as high stability to light, high clearing point, low minimum temperature of the liquid crystal phase, low viscosity, suitable optical anisotropy, large dielect...
|
|
WO/2014/125231A1 |
The invention relates to a method for the synthesis of 4-(heterocycloalkyl)-benzene-1,3-diol compounds of general formulae (I) and (III) wherein X can be an oxygen atom or a sulphur atom. The invention also relates to a method for the sy...
|
|
WO/2014/125911A1 |
Provided are: a liquid-crystalline compound which satisfies at least one property selected from high stability to light, a high clear point, a low lower-limit temperature of a liquid crystal phase, a low viscosity, proper optical anisotr...
|
|
WO/2014/124834A1 |
The present invention relates to a composition of matter comprising 1) at least 70 % of at least a compound of formula (I) in the form of any one of its stereoisomers or a mixture thereof, and wherein R represents - a hydrogen atom and t...
|
|
WO/2014/121666A1 |
Provided are new hydroxysafflor yellow A pharmaceutical salts as presented in formula (I), in particular new monomer compounds of potassium, ammonium, calcium, and magnesium salts of hydroxysafflor yellow A, preparation method therefor, ...
|
|
WO/2014/117741A1 |
Disclosed are heterocyclo compounds that have a formula represented by the following: and wherein X, R1, R2, R3, R4, R5, R6, and n are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for...
|
|
WO/2014/119787A1 |
Provided is a novel therapeutic drug that is useful in preventing or treating constipation, said drug comprising a compound capable of inhibiting SGLT1, in particular, a 4-isopropylphenyl glucitol compound represented by formula (I) or a...
|
|
WO/2014/111113A1 |
The present invention relates to compounds of formula (I) and, in particular, drugs containing at least one compound of formula I for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states, in the cause...
|
|
WO/2014/107803A1 |
The present document describes a synthesis of a class of gem-difluorinated C-glycoside compounds derived from podophyllotoxin, which may be used, but not exclusively, in oncology for the treatment of cancer. More particularly, the podoph...
|
|
WO/2014/108629A1 |
The invention relates to a compound having general formula (I) and the pharmaceutically acceptable salt thereof, and to the use of said compound for cosmetic or pharmaceutical uses.
|
|
WO/2014/106826A2 |
The invention relates to purified compound of Formula 1. The invention includes all isomeric forms and tautomeric forms of the compound of Formula 1 and pharmaceutically acceptable salts and derivatives thereof. The present invention fur...
|
|
WO/2014/094544A1 |
Provided are a phenyl C-glucoside derivative containing a deoxyglucose structure as represented by formula I, preparation method thereof, pharmaceutical composition containing same, and uses thereof in the preparation of drugs for treati...
|
|
WO/2014/096289A2 |
The present invention relates to a compound of formula (I), wherein: X is methyl or chlorine; R1 is methyl or chlorine; R2 is hydrogen, methyl, ethyl, n-propyl, cyclopropyl, vinyl, ethynyl, fluorine, chlorine, bromine, C1-C3alkoxy, C1-C2...
|
|
WO/2014/096699A1 |
C-xyloside compounds, compositions and use thereof to depigment the skin. The invention relates to a compound to depigment the skin comprising a compound of formula (I), wherein the compounds of formula (I) are xylose derivatives.
|
|
WO/2014/094511A1 |
The present invention relates to the preparation of intermediates of treprostinil, a preparation method for same, and the preparation of treprostinil thereby. Specifically, the invention relates to the compound of formula (VI), the prepa...
|
|
WO/2014/100438A1 |
The present invention provides compounds of formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W, X, n, s, t, and Ra are as described herein. The present invention relates generally to selective inhib...
|
|
WO/2014/098015A1 |
Provided are a 1-aryl-1-heterodiene compound represented by formula (I) or a salt thereof, and a pesticide containing said compound or salt thereof as an active ingredient. In formula (I), Q represents an aryl ring or the like; D2 repres...
|
|
WO/2014/089903A1 |
Disclosed are a liquid crystal compound containing a cyclobutyl and a difluoromethylenedioxy bonding group as well as a preparation method and an application thereof. The compound is shown in a formula (I). In the molecular structure of ...
|
|
WO/2014/090363A1 |
The invention relates to the use of 4-oxo-4H-pyran- or 4-oxo-l,4-dihydropyridine derivatives as protein-adhesive active substances, in particular as skin or hair-adhesive and/or skin or hair-binding UV-absorbers, and to the protection of...
|
